Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Intensity Therapeutics Inc banner
I

Intensity Therapeutics Inc
NASDAQ:INTS

Watchlist Manager
Intensity Therapeutics Inc
NASDAQ:INTS
Watchlist
Price: 3.88 USD 1.84% Market Closed
Market Cap: $10.5m
Write Note Create Alert Ask AI

Intensity Therapeutics Inc
R&D

R&D · Jun 2026 report

R&D declined in the latest quarter

-$1.8m
-53.4%
-$6.8m
+35.4%
-$6.1m
+22.5% YoY

Quarterly R&D reached -$1.8m, down 18.9% year over year and down 53.4% sequentially; LTM R&D was -$6.1m, down 5% from the preceding LTM observation of -$5.8m.

Sources: Income Statement

Growth

Horizon Past Forecast Difference
Quarter N/A N/A
1 year N/A N/A
3-year CAGR N/A N/A
5-year CAGR N/A N/A
10-year CAGR N/A N/A N/A

No analyst forecasts are available for R&D.

History

Statistic Value Reporting period
Average value -$6.4m Dec 2020 – Dec 2025
Median value -$5.5m Dec 2020 – Dec 2025
Highest value -$4.8m Dec 2023
Lowest value -$10.5m Dec 2024
Largest annual decline -$5.7m (-119.3%) Dec 2023 – Dec 2024

Intensity Therapeutics Inc
R&D Peer Comparison

Intensity Therapeutics Inc
Income Statement

USD
Metric FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Revenue
0 0 0 0 0 0
Operating Expenses
(6.2m) (8m) (7.6m) (8.3m) (16.6m) (12m)
Selling, General & Administrative
(1.2m) (2.2m) (2.4m) (3.5m) (6.1m) (5.2m)
R&D
(5.1m) (5.9m) (5.1m) (4.8m) (10.5m) (6.8m)
Operating Income
(6.2m) (8m) (7.6m) (8.3m) (16.6m) (12m)
Net Interest Income (Expense)
74k 2.6k (80k) 19k 314k 180k
Interest Expense
— — 82k 305k — —
Non-Recurring Items
— — 0 (2.3m) 0 —
Total Other Income
118.8k 115.5k 48k 24k 3k 186k
Pre-Tax Income
(6m) (7.9m) (7.6m) (10.5m) (16.3m) (11.6m)
Tax Provision
— — — — 0 —
Income from Continuing Operations
(6m) (7.9m) (7.6m) (10.5m) (16.3m) (11.6m)
Net Income
(6m) (7.9m) (7.6m) (11.9m) (16.3m) (11.6m)
EPS (Diluted)
(11.50) (15.06) (14.47) (21.63) (29.24) (8.56)

Intensity Therapeutics Inc
Glance View

Market Cap
10.5m USD
Industry
Biotechnology

Intensity Therapeutics is a clinical-stage biotechnology company that develops cancer treatments designed to be injected directly into a tumor. Its approach uses the tumor itself to help trigger an immune response, with the goal of shrinking the injected tumor and helping the body attack cancer elsewhere. The company’s lead work is focused on solid tumors, where doctors and cancer centers would be the users if the therapies reach market. The company does not sell approved drugs yet, so it does not have a traditional commercial customer base. Today it funds its work through equity financing and, if it signs them, research or licensing partnerships with larger drug companies. If its treatments are approved in the future, it would likely make money from product sales, licensing fees, and possible royalties. What makes Intensity Therapeutics different is that it is trying to turn a tumor into part of the treatment process instead of relying only on medicines that circulate through the whole body. That could fit alongside surgery, radiation, and other cancer drugs, and it gives the company a shot at becoming a specialty oncology developer focused on local tumor treatment rather than a broad drug maker.

INTS Intrinsic Value
LOCKED
Unlock
What is Intrinsic Value?

What is Intensity Therapeutics Inc's R&D?
R&D
-6.8m USD

Based on the financial report for Dec 31, 2025, Intensity Therapeutics Inc's R&D amounts to -6.8m USD.

What is Intensity Therapeutics Inc's R&D growth rate?
R&D CAGR 5Y
-6%

Over the last year, the R&D growth was 35%. The average annual R&D growth rates for Intensity Therapeutics Inc have been -10% over the past three years , -6% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join 358,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.